Thursday, April 3, 2025

Viz.ai Wins 2024 Edison Award™ for Innovation for Second Year in a Row

Related stories

Amazon simplifies access to Amazon Nova Gen AI models

Work with our foundation models on nova.amazon.com and access...

GE HealthCare & FPT Expand AI Healthcare Partnership

Global IT firm FPT and GE HealthCare announced a...

121G Launches HealthCoach, an AI Chronic Care Platform

121G Consulting proudly announces the release of its AI-based...

Covera Health Unveils ‘Protect Her™’ for Early Detection

New AI-powered platform leverages routine imaging to identify hidden...

Gayle deDie Named Cavallo’s SVP of Marketing

Cavallo, the leader in AI-powered Profit Maximization, announced Gayle...
spot_imgspot_img

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, announced that it has been named an Edison Award Winner in the 2024 Edison Awards, for the second year in a row. Viz PE with right ventricle/left ventricle ratio (RV/LV), the company’s AI software solution designed to detect and triage pulmonary embolism (PE) and right heart strain, was recognized in the Cardiovascular & Ophthalmic Innovations category. The prestigious Edison Awards, named after the American inventor Thomas Alva Edison, honor excellence in new product and service development, marketing, design and innovation.

“We are honored to win our second Edison Award for innovation,” said Dr. Chris Mansi, CEO and co-founder of Viz.ai. “When we started Viz.ai, we had a vision that by using artificial intelligence, we could help healthcare systems work smarter and faster, improving patient outcomes and ultimately saving lives. Every year in the United States, pulmonary embolism affects around 900,000 patients.1 The recognition of Viz PE, which has the potential to deliver faster and optimal care for patients with pulmonary embolism, validates our efforts to make this vision a reality.”

Also Read: Cured by Innovaccer Launches AI-Powered Healthcare Experience Platform (HXP) to Fuel Holistic Consumer Experience

Viz PE with automated RV/LV ratio measurement became an FDA-cleared AI-powered solution for the detection of suspected PE and assessment of right heart strain in 2022, in partnership with Avicenna.AI. PE is a serious condition, with untreated acute cases having a mortality rate as high as 30% within one month of diagnosis. Timely detection and triage by a multidisciplinary Pulmonary Embolism Response Team (PERT) are critical for patients. Recent data shows that the Viz PE solution combined with PERT activation significantly improved time to assessment and time to anticoagulation with a 74% reduction in in-hospital mortality risk.2

All nominations are reviewed by the Edison Awards’ Steering Committee and an executive judging body. The panel is composed of more than 2,000 senior business executives and academics from the fields of product development, design, engineering, science, marketing and education, as well as past winners.

Source: BusinessWire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img